Abstract
Two new preparations are under clinical trial for use in the treatment of ulcerative proctitis and left-sided colitis. One is 5-aminosalicylate, a component of sulfasalazine. This substance has virtually no immunomodulating capabilities. Evidence for efficacy equal to that of sulfasalazine in acute colitis has been obtained but its role in preventing recurrences is unknown. The other substance is tixocortol, a rapidly metabolized steroid, which has local antiinflammatory activity. Specific procedures of preparation and dosage remain to be established. Both preparations are administered as enemas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stenson WF: Pharmacology of sulfasalazine. Viewpoints Dig Dis 16(4):13–16, 1984
Peppercorn MA: Sulfasalazine. Pharmacology, clinical use, toxicity and related new drug development. Ann Intern Med 3:377, 1984
Schroder H, Campbell DES: Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 13:539–551, 1978
van Hees PAM, Bakker JH, van Tongeren JHM: Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulphasalazine. Gut 21:532–535, 1980
Schwartz AG, Targan SR, Saxon A, Weinstein WM: Sulfasalazine-induced exacerbation of ulcerative colitis. N Engl J Med 306:409–412, 1982
Hanauer SB, Schultz PA: Efficacy of 5-ASA enemas for steroid dependent ulcerative colitis. Gastroenterology 90(5):1449, 1986
MacDermott RP, Kane MG, Steele LL, Stenson WF: Inhibition of cytotoxicity by sulfasalazine. I. Sulfasalazine inhibits spontaneous cell-mediated cytotoxicity by control and inflammatory bowel disease peripheral blood and intestinal mononuclear cells. Immunopharmacology 11:101–109, 1986
Shanahan F, Niederlehner A, MacDermott RP, Stenson WF, Kane MG, Targan S: Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes. Immunopharmacology 11:111–118, 1986
Hanauer SB, Kirsner JB, Barrett WE: The treatment of left-sided ulcerative colitis with tixocortol pivalate (TP). Gastroenterology 90(5): 1449, 1986
LaRochelle P, Du Souich P, Bolte E, Lebrier J, Goyer R: Tixocortol pivalate, corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application. Clin Pharmacol Ther 33:343–350, 1983
Levinson RA: Comparative safety and efficacy of tixocortol pivalate enema versus hydrocortisone enema in the treatment of left sided ulcerative colitis.In Recent Developments in the Therapy of Inflammatory Bowel Disease. Proceedings of a symposium in Scottsdale, Arizona by the Johns Hopkins University Meyerhoff Center for Digestive Diseases, 1985
Author information
Authors and Affiliations
Additional information
Sponsored by NIH PHS grant 1P30 AM36200, “Inflammatory Bowel Disease Center”.
Rights and permissions
About this article
Cite this article
Karp, L.C., Targan, S.R. New enema treatments for inflammatory bowel disease. Digest Dis Sci 33 (Suppl 3), 85S–87S (1988). https://doi.org/10.1007/BF01538136
Issue Date:
DOI: https://doi.org/10.1007/BF01538136